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Abstract: CDK8 and CDK19 Mediator kinases are transcriptional co-regulators implicated in several
types of cancer. Small-molecule CDK8/19 inhibitors have recently entered or are entering clinical trials,
starting with breast cancer and acute myeloid leukemia (AML). To identify other cancers where these
novel drugs may provide benefit, we queried genomic and transcriptomic databases for potential
impact of CDK8, CDK19, or their binding partner CCNC. sgRNA analysis of a panel of tumor cell
lines showed that most tumor types represented in the panel, except for some central nervous system
tumors, were not dependent on these genes. In contrast, analysis of clinical samples for alterations in
these genes revealed a high frequency of gene amplification in two highly aggressive subtypes of
prostate cancer and in some cancers of the GI tract, breast, bladder, and sarcomas. Analysis of survival
correlations identified a group of cancers where CDK8 expression correlated with shorter survival
(notably breast, prostate, cervical cancers, and esophageal adenocarcinoma). In some cancers (AML,
melanoma, ovarian, and others), such correlations were limited to samples with a below-median
tumor mutation burden. These results suggest that Mediator kinases are especially important in
cancers that are driven primarily by transcriptional rather than mutational changes and warrant an
investigation of their role in additional cancer types.
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1. Introduction
The Mediator kinase CDK8 and its paralog CDK19, together with their binding partner Cyclin
C (CCNC), have been implicated through experimental studies in several malignancies, including
cancers of the colon [1–3], breast [4–7], prostate [8], pancreas [9], melanoma [10], and leukemias [11,12].
A number of small-molecule CDK8/19 inhibitors have been developed [13]. Such inhibitors showed
potentially beneficial effects on leukemia cell proliferation [11,12], tumor invasion [9,14], metastasis [3],
or tumor response to other anti-cancer drugs [4,6]. These effects of CDK8/19 inhibitors have been
demonstrated in several in vivo models, including lung [4], breast [6], colon [3], prostate cancers [15],
and leukemia [11]. The first clinical trials of Mediator kinase inhibitors have been conducted in estrogen
receptor–positive breast cancers (ClinicalTrials.gov Identifier: NCT03065010) and should be initiated
soon in acute myeloid leukemia (AML). It is now becoming imperative to identify other types of cancer
and categories of patients who could benefit from this new class of drugs.
Unlike better-known member of the cyclin-dependent kinase (CDK) family—such as CDK1,
CDK2, and CDK4/6—CDK8/19 do not mediate cell cycle progression but are only involved in
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transcription [16,17]. Furthermore, in contrast to the best-known transcriptional CDKs, such as CDK7
and CDK9, CDK8/19 activity is not required for transcription in general and does not affect normal
cell growth. Instead, CDK8/19 regulate transcription in a selective gene-specific context, primarily
enhancing the induction of silent genes as they become activated by various transcription factors [18].
Since CDK8/19 regulate transcription but not cell cycle progression, very few cancers, primarily a subset
of leukemias [11], were found to require CDK8/19 for their proliferation. On the other hand, selective
CDK8/19 inhibitors showed a variety of therapeutic activities in vivo that are not based on the inhibition
of tumor cell proliferation, such as suppression of tumor-promoting effects of chemotherapy-induced
DNA damage of host tissues [4], selective inhibition of metastatic but not primary growth of colon
cancers [3], and potentiation of in vivo effects of doxorubicin [4] or fulvestrant [6]. With this emerging
picture, it seems unlikely that cancers where CDK8/19 inhibitors would have a beneficial impact will
be defined as those that are growth-suppressed in vitro by CDK8/19 inhibition. On the other hand,
potential target cancers could be identified through informatic analysis of clinical data, which may
reveal tumor types where CDK8/19 or their binding partner Cyclin C (CCNC) would be amplified or
overexpressed or where CDK8/19 expression would be associated with bad prognosis. In the present
study, we have analyzed the available genomic and transcriptomic databases to identify cancers where
Mediator kinases are likely to play essential roles.
2. Materials and Methods
DepMap (https://depmap.org/portal/) analysis of the dependency of a panel of tumor cell lines
on individual genes [19,20] was conducted using the most recent (May 2019) CRISPR (Avana) Public
19Q2 and Combines RNAi (Broad, Novartis, Marcotte) databases.
cBioPortal for cancer genomics (https://www.cbioportal.org/) was used to query the alterations of
CDK8/CDK19/CCNC in clinical tumor samples at the DNA level and gene expression at the RNA level.
To maximize the likelihood of discovery of the alterations, DNA analysis was carried out using a set of
159 transcriptomic studies (TCGA- and non-TCGA) that were manually curated with no overlapping
samples (40,199 samples total). The TCGA dataset was used to query gene expression in different
cancers at the RNA level.
SurvExpress (http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp) was used to analyze
gene expression in three equally sized risk groups in the curated SurvExpress dataset of microarray
data in 808 colon cancers.
For most of the tumor types the survival analysis was carried out using the Pan-Cancer datasets
of the www.kmplot.com online tool [21]. The Pan-Cancer dataset is based on the TCGA data
generated using the Illumina HiSeq 2000 platform with survival information derived from a previous
publication [22]. In the survival analysis, each cutoff between the lower and upper quartiles was
analyzed by Cox proportional hazards regression and the best performing cutoff was used in the final
analysis. Kaplan-Meier survival plots were derived to visualize the survival curves, and hazard rates
were computed to numerically depict the difference between the two cohorts. The analyses were
performed using the “survival” package in the R statistical environment (http://www.r-project.org).
The final plots were formatted in Microsoft Excel using the WinStat 2019 extension (R Fitch Software,
Cambridge, MA, USA).
Tumor mutation burden (TMB) was determined for each sample by computing the total number of
mutated genes using the whole exome-sequencing data of the tumors. Genes with multiple mutations
were counted only once. The median number of mutations within the exome was computed separately
for each tumor type. Samples with higher mutation count were designated as TMB-high and those
with a lower mutation count as TMB-low. The correlation between survival and CDK8 expression was
analyzed in all samples combined and separately in TMB-high and -low samples.
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3. Results
3.1. Analysis of Tumor Cell Line Dependency on CDK8/CDK19/CCNC
For most classes of targeted drugs, an obvious approach to identifying potential target cancers
would be to screen a large panel of cell lines representing different tumor types for in vitro growth
inhibition by the drug. As a notable recent example, this approach was used to identify estrogen
receptor (ER)-positive breast cancer as a target disease for the inhibitors of CDK4/6 kinases essential
for cell cycle progression in G1 [23]. Following this analysis, CDK4/6 inhibitors underwent successful
trials and were rapidly approved for this disease [24]. Today, an online approach is available to predict
and approximate the results of such screening, thanks to the DepMap project conducted by the Broad
Institute in collaboration with the Wellcome Sanger Institute (www.depmap.org) [19,20]. In this project,
a comprehensive library of human genes has been knocked down or, more recently, knocked out
through CRISPR technology in large panels of human cell lines representing different types of cancer,
followed by enrichment/depletion analysis of gene-specific shRNAs or sgRNAs. The probability of
dependency of each cell line on the queried gene is represented as dependency scores, where the strong
negative values mark those cell lines where a given gene is especially important for growth or survival.
Figure 1 compares the overall distributions of DepMap dependency scores derived from CRISPR
analysis of a panel of 563 tumor cell lines and RNAi analysis of a panel of 713 cell lines, for cell cycle
CDKs (CDK1, CDK2, CDK4, and CDK6, left column), transcriptional CDKs (CDK7, CDK9, and CDK12,
middle column), and CDK8, CDK19, and CCNC (right column). In most cases, as expected, CRISPR
knockout produced much stronger effects than partial knockdown by RNAi. Analysis of cell cycle
CDKs identified CDK1 as a “common essential” gene, with the majority of cell lines of different types
dependent on CDK1 in both panels. CDK2 is classified as “common essential” by CRISPR analysis
but RNAi analysis classifies it as “strongly selective” (this selectivity pertains to ovarian cancer, not
shown). Strikingly, CDK4, the primary target of CDK4/6 inhibitors that showed a major clinical impact
in ER-positive breast cancers, was classified as “strongly selective” in both CRISPR and RNAi panels,
with the selectivity primarily associated with ER-positive cell lines, Ewing sarcoma and breast cancer
(not shown). CDK6 was classified as “strongly selective” by RNAi (but not CRISPR) analysis (Figure 1),
with selectivity for hematopoietic malignancies (not shown).
CRISPR knockout of the most commonly targeted transcriptional CDKs, CDK7, and CDK9,
showed drastic growth inhibition in almost all the cell lines, classifying these genes as “common
essential.” On the other hand, shRNA knockdown of CDK7 and CDK9 had much weaker growth
inhibitory effects, ranking these as neither “common essential” nor “strong selectivity.” Another
transcriptional CDK that has garnered recent attention, CDK12, produced similar results in the CRISPR
and RNAi analysis, with almost all the cell lines showing moderate dependency on CDK12, with no
apparent strong selectivity (Figure 1).
We then queried DepMap CRISPR and RNAi databases for dependency on CDK8, CDK19, and
CCNC (Cyclin C). Remarkably, analysis of co-dependency among all the genes revealed that CDK8
showed the highest co-dependency with CCNC and vice versa (Pearson correlation 0.51) in the CRISPR
database, indicating biological validity of this analysis (in the case of CDK19, no genes showed
co-dependency with a Pearson correlation above 0.30). However, the knockout or knockdown of
CDK8 or CDK19 showed the weakest overall growth-inhibitory activity among all the CDKs. The
knockout (but not the knockdown) of CCNC, the common binding partner of both CDK8 and CDK19,
and possibly CDK3, had a somewhat stronger growth inhibitory effect (Figure 1). Some tumor type
selectivity was suggested by this analysis, with the strongest dependency detected for CDK8 by CRSPR
assays in tumors of the central nervous system (designated Med Group 3) (Figure 2), and among the
other enriched lineages, hematopoietic malignancies were identified as dependent on CDK19 by RNAi
analysis (Figure 2).
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Figure 1. DepMap analysis of the dependency of tumor cell line panels in CRISPR (blue) and RNAi 
(violet) databases on the indicated CDKs. X-axis: dependency scores. Left column: cell cycle CDKs. 
Middle column: transcriptional CDKs. Right column: CDK8, CDK19, and CCNC. 
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Figure 1. DepMap analysis of the dependency of tumor cell line panels in CRISPR (blue) and RNAi
(violet) databases on the indicated CDKs. X-axis: dependency scores. Left column: cell cycle CDKs.
Middle column: transcriptional CDKs. Right column: CDK8, CDK19, and CCNC.
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Figure 2. DepMap representation f lineage enrichment i the analysis of dependency of CRISPR and
RNAi panels on CDK8, CDK19, and CCN .
3.2. Analysis of CDK8/CDK19/CCNC Alterations and Expression in Clinical Cancers
Our subsequent analysis concentrated on the data from clinical tumor samples rather than cell
lines. Using the cBioPortal for cancer genomics (https://www.cbioportal.org/) [25], we queried the
alterations of CDK8/CDK19/CCNC in clinical samples at the DNA level. This analysis was carried
out using a set of 40,199 non-overlapping tumor samples. Figure 3 shows the distribution of different
alterations of these three genes (gene amplification, deep deletions, mutations, fusions, multiple
alterations) in various subtypes of different cancers that were represented by at least 50 samples per
subtype and showed combined alteration frequencies of at least 3%.
The greatest alteration frequency for one or more of these genes was observed in prostate
neuroendocrine cancers and in castration-resistant prostate cancers (CRPC), where gene amplification
was found in 19.6% (11/56) and 18.6% (13/70) samples, respectively (data from [26]). A substantial
fraction (4.7%) of prostate adenocarcinomas (not further classified) showed deep deletions of one
or more of these three genes, but no such deletions were found in the CRPC or neuroendocrine
prostate cancer subtypes. Neuroendocrine prostate cancers and CRPC also showed the highest
frequency of gene amplification for CDK8, CDK19, and CCNC individually (Figure 3). After these
two subtypes of prostate cancer, gene amplification of one or more of CDK8, CDK19, and CCNC was
most common in several subtypes of cancers of the GI tract (tubular stomach adenocarcinoma (5%),
colon adenocarcinoma (3.9%), intestinal type stomach adenocarcinoma (3.7%), rectal adenocarcinoma
(3.6%)), as well as dedifferentiated liposarcoma (4.8%), bladder/urinary tract cancer (4.11%), and breast
invasive ductal carcinoma (3%) (Figure 3).
Cells 2019, 8, 821 6 of 16
Cells 2019, 8, x FOR PEER REVIEW 6 of 16 
 
 
Figure 3. cBioPortal analysis of frequencies of the indicated alterations of CDK8, CDK19, and CCNC 
(gene amplification red, deep deletion blue, mutation green) among different cancer subtypes. The 
analysis was carried out using a set of 159 studies that were manually curated with no overlapping 
samples (40,199 samples total). 
The greatest alteration frequency for one or more of these genes was observed in prostate 
neuroendocrine cancers and in castration-resistant prostate cancers (CRPC), where gene 
amplification was found in 19.6% (11/56) and 18.6% (13/70) samples, respectively (data from [26]). A 
substantial fraction (4.7%) of prostate adenocarcinomas (not further classified) showed deep 
deletions of one or more of these three genes, but no such deletions were found in the CRPC or 
neuroendocrine prostate cancer subtypes. Neuroendocrine prostate cancers and CRPC also showed 
the highest frequency of gene amplification for CDK8, CDK19, and CCNC individually (Figure 3). 
After these two subtypes of prostate cancer, gene amplification of one or more of CDK8, CDK19, and 
CCNC was most common in several subtypes of cancers of the GI tract (tubular stomach 
adenocarcinoma (5%), colon adenocarcinoma (3.9%), intestinal type stomach adenocarcinoma (3.7%), 
rectal adenocarcinoma (3.6%)), as well as dedifferentiated liposarcoma (4.8%), bladder/urinary tract 
cancer (4.11%), and breast invasive ductal carcinoma (3%) (Figure 3).  
Detailed “oncoprint” representation of CDK8/CDK19/CCNC alterations in all the types of cancer 
in the TCGA database [27] and in specific cancer types where the greatest numbers of alterations 
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In particular, CCNC and CDK19, both of which are located on chromosome 6 (6q16.2 and 6q21, 
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Figure 3. c i rt l l sis f fre e cies of the in icate alterations of 8, 19, and
(gene a plification red, deep deletion blue, mutation green) among different cancer subtypes. The
anal sis as carrie o t usi a set of 159 studies that were manual y curated ith no overlapping
sa ples (40,199 sa ples total).
Detailed “oncoprint” representation of CDK8/CDK19/CCNC alterations in all the types of cancer
in the TCGA database [27] and in specific cancer types where the greatest numbers of alterations
were found is shown in Figure 4. Examination of alterations in different cancers shows that CDK8,
CDK19 and CCNC can be amplified or deleted either independently of each other or in combinations.
In particular, CCNC and CDK19, both of which are located on chromosome 6 (6q16.2 and 6q21,
respectively), are frequently co-amplified or co-deleted. However, there are also cases where CCNC
(with or without CDK19) was co-amplified or co-deleted with CDK8, which is located on another
chromosome (13q12.13), indicating combined selective pressure on the binding partners. In particular,
co-amplification of CDK8 with CCNC and/or CDK19 was found in some cases of prostate and breast
cancer. Among the GI tract cancers, CDK8 was amplified much more frequently than CDK19 or CCNC
(Figure 4), with no a plification of CDK19 or CCNC found in colon cancers (not shown). In contrast,
CDK8, CDK19, and CCNC showed similar amplification frequencies in breast cancers and sarcomas.
Among other cancer types with relatively frequent alterations of CDK8, CDK19, or CCNC, we note
cancers of the uterus, where mutations of these genes were found more frequently than in the other
cancer types (Figure 4); most of these were missense mutations of unknown significance (Figure 4).
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3.3. Analysis of Survival Correlations for CDK8/CDK19/CCNC
With this information, we investigated whether the levels of CDK8/CDK19/CCNC RNA expression
in the tumors would show correlations with patient survival. We have previously carried out such
analysis for breast cancer, showing that CDK8 and related genes were associated with the failure
of systemic therapy in all the principal molecular subtypes of breast cancer [5]. The analysis was
now carried out using RNA-Seq data in the Pan-Cancer dataset of Kaplan-Maier plotter [28] website
(kmplot.com) as well as TCGA RNA-Seq data from other cancers that are not yet available at that
website but have been analyzed by the same methodology. The results of this analysis for correlations
of gene expression with the overall survival (OS) and relapse-free survival (RFS) (or with biochemical
relapse (BCR) in the case of prostate cancer) are summarized in Table 1. The analysis was aimed at
maximizing the number of cancer types that may be potentially affected by CDK8/19 and that would
therefore warrant further investigation, rather than to draw definitive conclusions about the role of
CDK8/19 in specific cancers. For this reason, correction for multiple hypothesis testing was omitted
from the analysis. CDK8 expression in most cases showed the strongest survival correlations. CDK19
expression frequently showed similar correlations to CDK8, whereas CCNC expression often showed
discordant correlations from CDK8 and CDK19 (Table 1).
Figure 6 presents examples of KM plots showing some of the strongest survival correlations for
CDK8 expression, including correlations with shorter BCR for prostate cancer and with shorter OS
for breast and cervical cancers and esophageal adenocarcinoma. In contrast, CDK8 expression was
correlated with longer OS in esophageal squamous cell carcinoma (Figure 6). Surprisingly, despite the
well-documented prognostic impact of CDK8 protein in colon cancer [29], no significant correlations
with OS or RFS were detected in the colon cancer RNA-Seq dataset (Table 1). On the other hand,
analysis of microarray data (which is available with a longer follow-up than RNA-Seq data) in the
curated SurvExpress dataset (http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp) of 808
colon cancers shows that expression of CDK8 and CDK19 (but not CCNC) was progressively increased
among patients separated into three risk groups according to disease-specific survival (Figure 7).
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Table 1. Correlations of CDK8/CDK19/CCNC expression with patient survival in different types of
cancer (OS, overall survival; RFS, relapse-free survival; BCR, biochemical relapse). The correlations for
most cancers were derived using Kaplan-Meyer plotter Pan-Cancer RNA-Seq dataset and for a subset
of cancers (AML, colon, melanoma, glioblastoma, glioma, prostate) from the available RNA-Seq data as
described in Materials and Methods. The hazard ratio (HR) and p values are in black when the gene
expression correlates with shorter survival and in green when it correlates with longer survival. p
values < 0.05 are boldfaced. The p values do not include correction for multiple hypothesis testing.
Cancer Type/Gene CDK8 CDK19 CCNC
n HR logrankp HR
logrank
p HR
logrank
p
Acute myeloid leukemia OS 132 0.63 0.049 0.6 0.026 0.61 0.045
Bladder Carcinoma
OS 405 1.34 0.063 0.71 0.023 1.37 0.042
RFS 187 1.83 0.091 4.87 0.004 2.68 0.024
Breast cancer
OS 1090 1.61 0.0031 1.43 0.038 1.62 0.01
RFS 255 1.75 0.0095 1.59 0.032 1.29 0.26
Colon cancer
OS 293 1.34 0.26 0.73 0.21 0.64 0.066
RFS 109 2.1 0.14 0.59 0.27 0.42 0.079
Cutaneous melanoma OS 458 1.26 0.093 0.58 0.00048 0.59 0.00046
Esophageal Squamous Cell Carcinoma OS 81 0.21 0.00053 0.48 0.072 0.53 0.11
RFS 54 2.57 0.19 1.49 0.42 2.06 0.25
Glioblastoma OS 152 0.66 0.022 1.28 0.24 0.63 0.019
Head-neck squamous cell carcinoma OS 500 1.46 0.008 0.6 0.0026 1.53 0.0028
RFS 124 1.49 0.32 0.43 0.11 2.45 0.016
Kidney renal clear cell carcinoma OS 530 1.32 0.11 0.49
5.7 ×
10−6 0.64 0.0028
RFS 117 0.3 0.017 NA* 0.027 0.16 0.045
Kidney renal papillary cell carcinoma OS 288 0.68 0.2 2 0.02 1.57 0.15
RFS 183 1.51 0.38 1.72 0.17 2.18 0.041
Liver hepatocellular carcinoma OS 71 1.68 0.0059 1.74 0.002 1.25 0.21
RFS 316 1.38 0.051 2.14 9.1 ×10−6 1.28 0.14
Low grade glioma OS 406 0.43 0.00025 1.43 0.058 1.91 0.0012
RFS 131 1.33 0.53 0.38 0.034 0.34 0.017
Lung adenocarcinoma OS 513 1.51 0.0092 0.72 0.07 1.35 0.1
RFS 300 1.53 0.049 1.34 0.17 0.83 0.38
Lung squamous cell carcinoma OS 501 1.11 0.44 0.76 0.046 0.86 0.29
RFS 300 1.49 0.14 2.28 0.015 1.63 0.14
Ovarian cancer
OS 374 1.27 0.072 1.52 0.0015 0.69 0.023
RFS 177 0.7 0.064 1.49 0.026 0.89 0.54
Pancreatic ductal adenocarcinoma
OS 177 1.27 0.25 1.2 0.4 0.8 0.3
RFS 69 2.42 0.1 5.31 0.013 1.62 0.25
Pheochromocytoma and Paraganglioma OS 178 NA* 0.11 13.46 0.0029 4.65 0.052
RFS 159 7.96 0.033 0.24 0.18 3.18 0.29
Prostate adenocarcinoma
OS 494 4.36 0.019 0.58 0.4 0.48 0.35
BCR 337 2.46 0.011 2.09 0.039 0.44 0.082
Rectum adenocarcinoma
OS 165 0.59 0.24 0.54 0.12 0.28 0.014
RFS 47 5.37 0.031 NA* 0.16 0.11 0.027
Sarcoma
OS 259 1.55 0.031 1.41 0.09 1.79 0.0038
RFS 152 0.71 0.17 1.57 0.074 0.58 0.068
Stomach adenocarcinoma
OS 375 0.55 0.0011 0.81 0.21 0.81 0.21
RFS 215 0.32 0.00037 1.45 0.3 0.78 0.46
Testicular Germ Cell Tumor
OS 134 0.1 0.015 NA* 0.098 5.09 0.12
RFS 105 2.37 0.046 0.59 0.19 5.15 0.0029
Thymoma OS 119 0.28 0.061 0.07 0.00005 0.15 0.0037
Thyroid carcinoma OS 502 0.67 0.43 0.26 0.055 2.1 0.14
RFS 353 2.17 0.14 2.19 0.047 0.4 0.12
Uterine corpus endometrial carcinoma OS 543 1.89 0.0037 1.66 0.023 0.63 0.059
RFS 422 1.43 0.22 1.88 0.038 1.57 0.1
* number of events too low to compute a statistically valid HR value.
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Figure 7. Levels of CDK8/CDK19/CCNC expression in three equal-size groups of colon cancers patients
stratified by increasing risk, in the curated SurvExpress dataset (http://bioinformatica.mty.itesm.mx:
8080/Biomatec/SurvivaX.jsp) of 808 colon cancers.
Surprisingly, neither survival correlations nor the analysis of CDK8/CDK19/CCNC gene alterations
or expression provided any rationale for using CDK8/19 inhibitors to target acute myeloid leukemia
(AML), the only disease where a subset of cell lines was found to be highly susceptible to
anti-proliferative effects of CDK8/19 inhibition [11,12]. In fact, CDK8/CDK19/CCNC expression in
AML was correlated with longer survival (Table 1). Therefore, we have analyzed survival correlations
of CDK8 expression in AML samples stratified by different criteria. One of these criteria was tumor
mutation burden (TMB), determined in tumor samples that were analyzed by DNA exome sequencing.
Above-median numbers of mutated genes per sample (based on the mutation frequency calculated
for each tumor type) were defined as high-TMB and below-median levels as low-TMB. When AML
samples were separated by this criterion, CDK8 expression was found to correlate with longer OS in
samples with high TMB and with shorter OS in samples with low TMB (Figure 8). Stratification into
groups with high and low TMB revealed other cancers where CDK8 expression became a marker of
shorter OS only in tumors with low TMB, namely melanoma, ovarian adenocarcinoma and renal clear
cell carcinoma (Figure 8). Similar correlations were seen in pancreatic cancer and sarcomas albeit the
correlations with shorter OS in low-TMB samples showed p values > 0.05 (not shown). Stratification
by TMB didn’t change the nature of CDK8 correlations in other cancer types.
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4. Discussion
The analysis presented above highlights some unique aspects of Mediator kinases as cancer drug
targets. In contrast to most targets of tumor-suppressive drugs (such as, for example, CDK4/6), very few
tumor cell lines showed pronounced dependency on CDK8/CDK19/CCNC in DepMap analysis. Hence,
the results of this analysis suggest that growth inhibition of tumor cell lines is not a very productive
approach to identifying disease targets for CDK8/19 inhibitors. This conclusion agrees, in particular,
with the experimental results obtained in colon cancer, where CDK8 has been identified as a frequently
amplified oncogene and a negative prognostic marker [1,29] but CDK8/19 inhibitors did not suppress
in vitro growth even of those cell lines where CDK8 was amplified or overexpressed. Nevertheless,
small-molecule CDK8/19 inhibitors did show beneficial therapeutic effects in colon cancer models but
these effects were observed only in vivo and specifically when targeting metastatic growth of colon
cancers in the liver [3]. Hence, it stands to reason that the analysis of the role of the Mediator kinase in
different cancers should take in account primarily in vivo correlations.
Analysis of CDK8/CDK19/CCNC alterations identified several cancer subtypes where these genes
were frequently altered. The alterations included gene amplification, which is the alteration most likely
to indicate a role for a gene in carcinogenesis and tumor progression, deep deletions that could be
indicative of a tumor suppressor, as well as mutations in these genes. Both deletions and amplifications
were especially notable among prostate cancers, where increasing expression of CDK19 and CDK8
has been shown to be associated with carcinogenesis and acquisition of the largely incurable CRPC
phenotype [8]. Two treatment-resistant subtypes of prostate cancer, CRPC and neuroendocrine prostate
cancers, showed the highest (close to 20%) amplification frequencies of one or more of these genes.
On the other hand, a substantial fraction (close to 5%) of prostate cancers that did not belong to these
two subtypes showed deep deletions of CDK8/CDK19/CCNC, suggesting that such deletions may
indicate a particular subtype of prostate cancers where the Mediator kinase plays the opposite role to
its carcinogenesis-associated effects in the majority of these tumors.
Other cancers with a relatively high frequency of gene amplification included GI cancers, among
which colon cancers, in particular, showed a unique specificity of gene amplification for CDK8 over
CDK19, in agreement with the original report [1]. The other cancers with a substantial frequency
of CDK8/CDK19/CCNC gene amplification were breast cancers and sarcomas. On the other hand,
uterine cancers were unique in showing a high frequency of point mutations in CDK8/CDK19/CCNC.
Notably, the latter cancers are also characterized by frequent mutations of MED12 [30], a protein
that interacts with the Mediator kinase in the CDK module of the Mediator, although MED12 also
has Mediator-independent functions in the cytoplasm [31]. The impact of the CDK8/CDK19/CCNC
mutations found in uterine cancers is unknown, but we note that uterine cancers were also one of the
types that showed correlations between the expression of CDK8 and CDK19 and shorter survival.
Analysis of TCGA RNA expression data for these three genes showed that CDK8 expression
was the most variable, including cases with an apparent silencing of this gene. In contrast, CDK19
RNA expression was relatively uniform among different cancers, with a prominent elevation in
prostate cancers, where CDK19 has been already identified as a marker of carcinogenesis and tumor
progression [8]. Interestingly, the RNA levels of CDK19 were generally much higher than those of
CDK8. In contrast, at the protein level, CDK19 expression in tumor cell lines (other than prostate
cancer) is generally much lower than the expression of CDK8 (our unpublished data), suggesting
post-transcriptional regulation of CDK19.
Given the high range of CDK8 expression in tumor samples, it is not surprising that CDK8 RNA
levels also showed the best correlations with decreased survival in several tumor types. In addition to
confirming the previously reported survival correlations for breast and prostate cancers [6,8], several
new tumor types showed a correlation between higher CDK8 levels and shorter survival, suggesting
that these cancers could be potential targets for CDK8/19 inhibitor therapy. These include cervical
cancer, esophageal adenocarcinoma, lung adenocarcinoma, liver hepatocellular carcinoma, head and
neck squamous cell carcinoma, uterine endometrial carcinoma, and sarcomas. Interestingly, colon
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cancers for which CDK8 correlations with shorter survival have been reported at the protein level [8]
did not show such correlations in the RNA-Seq database, although CDK8 expression was associated
with higher risk in the microarray database, where longer follow-up times were available for survival
correlations. In addition to this difference between microarray and RNA-Seq databases, regulation of
CDK8 expression at protein level in colon cancers cannot be ruled out.
Remarkably, some cancers, in particular stomach adenocarcinoma and esophageal squamous cell
carcinoma, showed the opposite correlations for CDK8 expression, as it was associated with longer
patient survival, suggesting that the Mediator kinase may play a tumor-suppressive role in such
cancers. It was especially surprising that CDK8 and CDK19 expression showed correlations (albeit
weak) with a longer rather than shorter survival in AML, the only disease where a large subset of
cell lines was found to be highly susceptible in vitro to CDK8/19 inhibitors [11,12]. We have found,
however, that stratifying cancers by high and low mutation burden changes the correlation of CDK8
expression from shorter to longer survival. CDK8 expression was associated with shorter survival
among cancers with below-median mutation burden, not only in AML but also in melanoma, ovarian
adenocarcinoma and renal clear cell carcinoma. The observed association of the impact of CDK8
in cancers with low mutation burden is reasonable, since CDK8 regulates transcription and may be
expected therefore to have a greater impact in those cancers that are driven primarily by changes in
gene expression rather than mutations.
The identification of cancer types where CDK8/CDK19/CCNC are frequently amplified or where
their expression correlates with survival suggests a potential role of CDK8/19 in the pathogenesis of
such cancers or their treatment response, but it does not automatically mean that such cancers will
respond to CDK8/19 inhibitor therapy. Nevertheless, the new correlations identified here provide an
obvious impetus for investigating the role of this regulator in the affected types of cancer through
detailed pathological analysis and in vivo tumor model studies.
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